促进头颈癌幸存者淋巴水肿和纤维化自我管理的干预项目多中心随机临床试验研究方案(PROMISE试验)
本研究为一项为期3年、多中心、三臂平行组随机临床试验(N=204),纳入成年头颈癌幸存者,随机分为常规护理组、面对面淋巴水肿和纤维化自我管理项目(LEF-SMP)组及远程医疗LEF-SMP组。主要终点为淋巴水肿和纤维化严重程度,次要终点包括症状负担、功能障碍、生活质量、知识、技能、自我效能及自我护理依从性,在基线及干预后3、6、9个月测量。研究旨在评估标准化LEF-SMP降低淋巴水肿和纤维化相关症状负担及功能障碍、改善生活质量的效果。
要点
- 本试验为多中心三臂随机对照试验,计划样本量204例成年头颈癌幸存者。
- 干预组分别接受面对面或远程医疗LEF-SMP,对照组接受常规护理。
- 主要终点为淋巴水肿和纤维化严重程度,次要终点包括症状负担、功能障碍、生活质量等。
核心结论
- 本研究将检验标准化淋巴水肿和纤维化自我管理项目(LEF-SMP)能否降低头颈癌幸存者的淋巴水肿和纤维化负担及其影响。
- 作者预计干预将改善淋巴水肿和纤维化自我管理,减少相关症状负担和功能障碍,并提升生活质量及淋巴水肿和纤维化相关知识和技能。
研究设计与样本
- 研究设计为为期3年、多中心、三臂平行组随机临床试验,计划样本量N=204。
- 目标人群为成年头颈癌幸存者。
- 招募、数据收集和研究干预在两家综合医疗中心进行,包括宾夕法尼亚大学健康系统(Penn Medicine)和范德堡-英格拉姆癌症中心(VICC)。
- 参与者随机分为三组:第1组常规护理,第2组面对面LEF-SMP,第3组远程医疗LEF-SMP。
- 主要终点为淋巴水肿和纤维化严重程度;次要终点包括淋巴水肿和纤维化相关症状负担、功能障碍、生活质量、淋巴水肿和纤维化相关知识、技能、自我效能及自我护理依从性;所有终点在基线(干预前)及干预后3、6、9个月测量。
局限性
- 原文指出,尽管缺乏前瞻性数据,但自我管理项目可能减少淋巴水肿和纤维化进展并减轻相关功能障碍和症状负担。
- 原文指出,头颈癌幸存者长期淋巴水肿和纤维化自我护理的障碍包括缺乏标准化自我护理方案以及缺乏淋巴水肿和纤维化相关知识、技能、自我效能和依从性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lymphedema and fibrosis (LEF) secondary to head and neck cancer (HNC) treatment is a chronic process and a lifelong commitment to self-care. Although prospective data is lacking, a program of self-management may reduce LEF progression and minimize associated functional impairments and symptom burden. Barriers to long-term LEF self-care include lack of standardized self-care protocols as well as lack of LEF-related knowledge, skills, self-efficacy and adherence among HNC survivors. The objective of this study is to evaluate the effectiveness of a standardized lymphedema and fibrosis self-management program (LEF-SMP) in reducing LEF-associated symptom burden and functional deficits, thereby improving quality of life (QOL). METHODS: We will conduct a 3-year, multi-site, 3-arm parallel-group, randomized clinical trial (N = 204). The targeted population consists of adult HNC survivors. Eligible participants will be randomized to one of the following groups: Group 1, usual care; Group 2, in-person LEF-SMP; and Group 3, telehealth LEF-SMP. Recruitment, data collection, and study intervention will be conducted at two comprehensive medical centers including University of Pennsylvania Health System (Penn Medicine) and Vanderbilt-Ingram Cancer Center (VICC). Primary study endpoint is LEF severity; and secondary study endpoints include LEF-related symptom burden, functional impairments, QOL, LEF-related knowledge, skills, self-efficacy, and self-care adherence. All above-mentioned primary and secondary endpoints will be measured at the baseline (pre-intervention), and 3-, 6-, and 9-month post-intervention. DISCUSSION: This study will test whether the standardized lymphedema and fibrosis self-management program (LEF-SMP) has the ability to decrease the burden of LEF and its impact on HNC survivors. We anticipate that the intervention will improve LEF self-management, reduce LEF-associated symptom burden and functional impairments, and enhance QOL as well as LEF-related knowledge and skills in HNC survivors. TRIAL REGISTRATION: This study was registered on November 01, 2023, at ClinicalTrials.gov, a service of the US National Institute of Health (NCT06125743). The URL of the trial registry record: https://clinicaltrials.gov/study/NCT06125743 .
引用
- Deng J, Abene J, Huang L, et al. Study protocol for a multi-site randomized clinical trial of an intervention program to promote self-management among head and neck cancer survivors with lymphedema and fibrosis [PROMISE trial]. Trials. 2025. PMID: 41084063. doi:10.1186/s13063-025-09089-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。